Novo Nordisk's NVO latest analysis showing its CagriSema injection capable of achieving 25% weight loss in average adult women adds yet another feather to the weight-loss market's cap, reinforcing the rapid pace of innovation that has defined the past year. The Danish drugmaker said its next-generation injection achieved 25% weight reduction at 68 weeks in adult women, versus just 3% for placebo, with consistent results across menopausal stages. The finding builds on a market already transformed by GLP-1 therapies, as pharma giants like Eli Lilly LLY and a few others, apart from NVO, race to establish their dominance in the global GLP-1 receptor agonist market, projected to reach $185 billion by 2033 (as per Grand View Research).
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.